AbbVie Inc. SEC filings ABBV
AbbVie Inc. has 1,006 filings in SEC EDGAR's recent list, going back to May 9, 2017. Its latest annual report, Form ARS, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Mar 23, 2026 | — |
| DEF 14A | Proxy statement | Mar 23, 2026 | May 8, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 9, 2026 | Mar 9, 2026 |
| DEFA14A | Additional proxy material | Mar 24, 2025 | — |
| DEF 14A | Proxy statement | Mar 24, 2025 | May 9, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 10, 2025 | May 9, 2025 |
| DEFA14A | Additional proxy material | Mar 18, 2024 | — |
| DEF 14A | Proxy statement | Mar 18, 2024 | May 3, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 4, 2024 | May 3, 2024 |
| DEFA14A | Additional proxy material | Mar 28, 2023 | — |
| DEFA14A | Additional proxy material | Mar 21, 2023 | — |
| DEFA14A | Additional proxy material | Mar 20, 2023 | — |
| DEF 14A | Proxy statement | Mar 20, 2023 | — |
| PRE 14A | Preliminary proxy statement | Mar 6, 2023 | — |
| DEFA14A | Additional proxy material | Mar 21, 2022 | — |
| DEF 14A | Proxy statement | Mar 21, 2022 | May 6, 2022 |
| PRE 14A | Preliminary proxy statement | Mar 7, 2022 | May 6, 2022 |
| DEFA14A | Additional proxy material | Mar 22, 2021 | — |
| DEF 14A | Proxy statement | Mar 22, 2021 | May 7, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 8, 2021 | May 7, 2021 |
| DEFA14A | Additional proxy material | Mar 24, 2020 | — |
| DEF 14A | Proxy statement | Mar 23, 2020 | May 8, 2020 |
| PRE 14A | Preliminary proxy statement | Mar 9, 2020 | May 8, 2020 |
| DEFA14A | Additional proxy material | Mar 22, 2019 | — |
| DEF 14A | Proxy statement | Mar 22, 2019 | May 3, 2019 |
| PRE 14A | Preliminary proxy statement | Mar 8, 2019 | May 3, 2019 |
| DEFA14A | Additional proxy material | Mar 19, 2018 | — |
| DEF 14A | Proxy statement | Mar 19, 2018 | May 4, 2018 |
| PRE 14A | Preliminary proxy statement | Mar 7, 2018 | May 4, 2018 |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABBV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- North Chicago, IL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1551152
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.